Published in final edited form as:

Inorg Chem. 2018 September 04; 57(17): 10608–10615. doi:10.1021/acs.inorgchem.8b01225.

Photochemotherapeutic Properties of a Linear Tetrapyrrole Palladium(II) Complex displaying an Exceptionally High Phototoxicity Index

Andrea M. Potocny^{†,‡}, Rachel S. Riley^{†,‡}, Rachel K. O'Sullivan[‡], Emily S. Day^{*,‡,§,||}, and Joel Rosenthal^{*,†}

[†]Department of Chemistry and Biochemistry, University of Delaware, Newark, Delaware 19716, United States

[‡]Department of Biomedical Engineering, University of Delaware, Newark, Delaware 19716, United States

[§]Department of Materials Science and Engineering, University of Delaware, Newark, Delaware 19716, United States

^{||}Helen F. Graham Cancer Center and Research Institute, Newark, Delaware 19713, United States

Abstract

Photodynamic therapy (PDT) represents a minimally invasive and highly localized treatment strategy to ablate tumors with few side effects. In PDT, photosensitizers embedded within tumors are activated by light and undergo intersystem crossing, followed by energy transfer to molecular oxygen, resulting in the production of toxic singlet oxygen (¹O₂). Previously, we reported a robust, linear tetrapyrrole palladium(II) complex, **Pd[DMBil1]**, characterized by its facile and modular synthesis, broad absorption profile, and efficient ¹O₂ quantum yield of $\Phi = 0.8$ in organic media. However, the insolubility of this porphyrinoid derivative in aqueous solution prevents its use under

*Corresponding Authors: emilyday@udel.edu. (E.S.D.); joelr@udel.edu. (J.R.).

[†]Author Contributions

These authors contributed equally. The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications Web site. The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.inorgchem.8b01225.

Experimental procedures, additional **Pd[DMBil1]-PEG₇₅₀** characterization data, and photodynamic therapy data (PDF)

The authors declare no competing financial interest.

biologically relevant conditions. In this work, we report the synthesis of **Pd[DMBil1]-PEG₇₅₀**, a water-soluble dimethylbiladiene derivative that is appended with a poly(ethylene) glycol (PEG) functionality. Characterization of this complex shows that this PEGylated biladiene architecture maintains the attractive photophysical properties of the parent complex under biologically relevant conditions. More specifically, the absorption profile of **Pd[DMBil1]-PEG₇₅₀** closely matches that of **Pd[DMBil1]** and obeys the Beer–Lambert Law, suggesting that the complex does not aggregate under biologically relevant conditions. Additionally, the emission spectrum of **Pd[DMBil1]-PEG₇₅₀** retains the fluorescence and phosphorescence features characteristic of **Pd[DMBil1]**. Importantly, the PEGylated photosensitizer generates $^1\text{O}_2$ with $\Phi = 0.57$, which is well within the range to warrant interrogation as a potential PDT agent for treatment of cancer cells. The **Pd[DMBil1]-PEG₇₅₀** is biologically compatible, as it is taken up by MDA-MB-231 triple negative breast cancer (TNBC) cells and has an effective dose (ED_{50}) of only $0.354\ \mu\text{M}$ when exposed to $\lambda_{\text{ex}} > 500\ \text{nm}$ light for 30 min. Impressively, the lethal dose (LD_{50}) of **Pd[DMBil1]-PEG₇₅₀** without light exposure was measured to be $1.87\ \text{mM}$, leading to a remarkably high phototoxicity index of ~ 5300 , which is vastly superior to existing photosensitizers that form the basis for clinical PDT treatments. Finally, through flow cytometry experiments, we show that PDT with **Pd[DMBil1]-PEG₇₅₀** induces primarily apoptotic cell death in MDA-MB-231 cells. Overall these results demonstrate that **Pd[DMBil1]-PEG₇₅₀** is an easily prepared, biologically compatible, and well-tolerated photochemotherapeutic agent that can efficiently drive the photoinduced apoptotic death of TNBC cells.

INTRODUCTION

Photodynamic therapy (PDT) is used clinically as a non-invasive treatment for solid tumors. In PDT, photosensitizing compounds are either intratumorally or intravenously injected and circulate throughout the body prior to irradiation of the tumor site.¹ Photosensitizers present within the illuminated tissue absorb light and transfer energy to ground-state molecular oxygen to produce toxic $^1\text{O}_2$ that ultimately induces localized cell death (Scheme 1). PDT is regarded as a promising treatment strategy for certain types of cancers² and skin conditions,³ because it is less invasive than surgical removal,⁴ has fewer side effects than radiation or chemotherapy,^{5–9} and can, in some cases, stimulate an antitumor immune response.^{10,11}

Several photosensitizers, most of which belong to the porphyrinoid family of macrocyclic tetrapyrroles, have been approved for use in PDT.^{12–14} However, widespread clinical use of PDT has been hindered, at least in part, because existing $^1\text{O}_2$ photosensitizers lack the photophysical and pharmacological attributes required for an optimal phototherapeutic agent. An ideal photosensitizer would be simple to synthesize and purify, demonstrate strong absorption of 600–850 nm light, which can penetrate deeper into tissues, and generate $^1\text{O}_2$ with a high quantum yield during irradiation. It is also critical that a photosensitizer for PDT be relatively nontoxic in the absence of light to minimize off-target side effects. Lastly, water solubility is critical to ensure stability during storage or intravenous injection and to prevent aggregation-induced attenuation of the $^1\text{O}_2$ quantum yield.

We recently demonstrated that the linear tetrapyrrole metal complex palladium 10, 10-dimethyl-5, 15-bis-(pentafluorophenyl)biladiene (**Pd[DMBil1]**, structure shown in Scheme

2) is capable of absorbing light up to $\lambda \approx 600$ nm and sensitizing $^1\text{O}_2$ with a high quantum yield ($\Phi \approx 0.8$) that is on par with those of photosensitizers currently used in PDT.¹⁵ Importantly, **Pd[DMBil1]** is easily synthesized in four steps from commercially available starting materials,¹⁵ and it can be purified and isolated using modular methods. While these traits suggest that the **Pd[DMBil1]** core is well-suited for interrogation as a PDT agent, this compound's complete lack of water solubility has precluded such studies.

The addition of poly(ethylene) glycol (PEG) substituents is commonly employed in the development of therapeutics, since PEGs generally show excellent biocompatibility and lend high water solubility.^{16–19} In the present study, we modified the **Pd[DMBil1]** photosensitizer with a PEG functionality to overcome the inherent hydrophobicity of the biladiene architecture. We demonstrate that the addition of this PEG functionality endows the dimethylbiladiene complex with water solubility while having little effect on its photophysical properties, thus generating a biocompatible compound, **Pd[DMBil1]-PEG₇₅₀**, that retains the ability to generate $^1\text{O}_2$ with a high quantum yield under biologically relevant conditions. Additionally, we demonstrate that, while this biladiene complex is highly nontoxic in the dark, it can serve as an extremely potent chemotherapeutic agent for treatment of triple negative breast cancer (TNBC) cells and drives apoptotic cell death with a remarkable phototoxicity index of ~ 5300 .

RESULTS AND DISCUSSION

Pd[DMBil1]-PEG₇₅₀ is readily accessible from unfunctionalized **Pd[DMBil1]**, which is readily prepared (Scheme 2) in four steps using methodology previously developed for the synthesis of biladienes^{15,20} and related tetrapyrroles containing sp^3 hybridized *meso*-carbons.^{21–23} PEGylation of the parent **Pd[DMBil1]** architecture was facilitated by the presence of the two pentafluorophenyl substituents at the 5- and 15-positions, which can be derivatized via nucleophilic aromatic substitution of the *para*-fluorine substituents.^{24–26} As shown in Scheme 2, treatment of **Pd[DMBil1]** with mercaptoacetic acid and NEt_3 at 90°C in dimethylformamide (DMF) for 1 h afforded the monomercaptoacetic acid-substituted product (**Pd[DMBil]-SCH₂CO₂H**) in better than 75% yield following purification by flash chromatography. PEGylation of **Pd[DMBil]-SCH₂CO₂H** was achieved through conversion of the mercaptoacetic acid substituent into an *N*-(methoxyPEG)mercaptoacetamide using carbodiimide coupling chemistry.^{27,28} **Pd[DMBil]-SCH₂CO₂H** was initially reacted with *N*-hydroxysuccinimide (NHS) and 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide hydrochloride (EDC) to form an NHS mercaptoacetate intermediate. Further treatment with triethylamine and a methoxy-PEG-amine with an average molecular weight of 750 Da resulted in the formation of **Pd[DMBil1]-PEG₇₅₀**, as is shown in Scheme 2. Detailed synthetic procedures and characterization data for all new compounds shown in Figure 2 are detailed in the Supporting Information.

The visible absorption profile of **Pd[DMBil1]-PEG₇₅₀** has three features centered at 402, 483, and 540 nm in methanol (Figure 1 and Table 1). Aside from showing a slight enhancement of the feature at 483 nm, this absorption profile is nearly identical to that of **Pd[DMBil1]** in methanol, suggesting that introduction of the thioether and PEG chain at the *para* position of one biladiene C_6F_5 substituent has little effect on the electronic structure of

the palladium tetrapyrrole core. In a pH 7.4 phosphate-buffered saline (PBS) solution the absorption spectrum of **Pd[DMBil1]-PEG₇₅₀** shows a bathochromic shift relative to its appearance in methanol. Although the full width at half-maximum (fwhm) of the most prominent absorption feature of the PEGylated derivative increases slightly from 63 nm in methanol to 67 nm in PBS, both of these values are smaller than the fwhm of the corresponding absorption feature of **Pd[DMBil1]** in methanol (73.5 nm). Furthermore, solutions of **Pd[DMBil1]-PEG₇₅₀** behave in accordance with the Beer–Lambert Law when dissolved in either methanol or PBS at concentrations ranging from 4 to 24 μM (Supporting Information Figure S2). Self-aggregation of other tetrapyrroles under aqueous conditions has been associated with broadened absorption features^{29–31} and deviations from the Beer–Lambert Law,³² so the observation that **Pd[DMBil1]-PEG₇₅₀** does not exhibit such behavior indicates that aggregation for this system should be insignificant. The **Pd[DMBil1]-PEG₇₅₀** complex is also resistant to photodegradation, as the UV–vis absorption spectrum for this construct in PBS (24.0 μM) showed no substantial changes over the course of 2 h of irradiation with 500 or 550 nm light (Figure S3).

The emission properties of the **Pd[DMBil1]** complex in nitrogen-saturated methanol are also largely unaffected by PEGylation. As has been previously observed for **Pd-[DMBil1]**,¹⁵ excitation of **Pd[DMBil1]-PEG₇₅₀** with 500 nm light elicits weak fluorescence from 500 to 700 nm as well as phosphorescence from 700 to 850 nm (Figure 2). Table 1 shows that, while the fluorescence emission maximum of **Pd[DMBil1]-PEG₇₅₀** in methanol is red-shifted by 11 nm compared with that of **Pd[DMBil1]**, the fluorescence quantum yield of the PEGylated derivative ($\Phi_{\text{fl}} = 1.4 \times 10^{-4}$) is essentially identical to that of the parent compound ($\Phi_{\text{fl}} = 1.3 \times 10^{-4}$). The phosphorescence emission maximum shows a much smaller red shift from 753 nm for **Pd[DMBil1]** to 756 nm for **Pd[DMBil1]-PEG₇₅₀**, and the phosphorescence quantum yield decreases slightly from $\Phi_{\text{ph}} = 1.3 \times 10^{-4}$ for **Pd[DMBil1]** to $\Phi_{\text{ph}} = 7.8 \times 10^{-5}$ for **Pd[DMBil1]-PEG₇₅₀**.

The emission characteristics of **Pd[DMBil1]-PEG₇₅₀** in nitrogen-saturated PBS (pH 7.4) were also investigated; however, irradiation with 460 nm light under these conditions only resulted in one emission feature stretching from 500 to 700 nm corresponding to fluorescence (Table 1 and Figure S4). As compared with its fluorescence in methanol, the fluorescence of **Pd[DMBil1]-PEG₇₅₀** in PBS is further red-shifted, with an emission maximum at 580 nm and a quantum yield of $\Phi_{\text{fl}} = 2.0 \times 10^{-4}$ in (Table 1). Given that fluorescence quenching is a well-documented consequence of porphyrinoid self-aggregation,³³ the lack of attenuation of Φ_{fl} in PBS provides further evidence that **Pd[DMBil1]-PEG₇₅₀** does not tend to aggregate in aqueous environments. Failure to detect phosphorescence from the PEGylated derivative in PBS may be attributed to shortening of the triplet excited-state lifetime via energy transfer to a H₂O overtone.

In prior work, we showed that air efficiently quenches the excited triplet state of **Pd[DMBil1]** in methanol, resulting in quenching of the biladiene's phosphorescence due to efficient energy transfer to molecular oxygen.¹⁵ This phenomenon was also manifest in the ability of **Pd[DMBil1]** to photosensitize ¹O₂ generation with an impressive quantum yield of $\Phi = 0.8$, as quantified using diphenylisobenzofuran (DPBF)³⁴ as an ¹O₂ probe and

[Ru(bpy)₃][PF₆]₂ as an actinometer ($\Phi = 0.81$).³⁵ Similarly, the phosphorescence observed for **Pd[DMBil1]-PEG₇₅₀** in methanol under an inert atmosphere was quenched upon introduction of air (Figure 2b) to the sample. Quantification of the ability of the **Pd[DMBil1]-PEG₇₅₀** complex to sensitize the formation of ¹O₂ produced a quantum yield of $\Phi = 0.57$ following irradiation with 550 nm light. The slight decrease in Φ value for the PEGylated biladiene complex may be attributed to a decrease in the O₂ diffusion rate within the immediate vicinity of the photosensitizer due to partial shielding by the PEG moiety.³⁶ Nonetheless, the ability of **Pd[DMBil1]-PEG₇₅₀** to sensitize the formation of ¹O₂ ($\Phi = 0.57$) is competitive with commercial photosensitizers employed for PDT.¹³

Although **Pd[DMBil1]-PEG₇₅₀** does not exhibit phosphorescence in PBS solutions (vide supra) this complex is capable of sensitizing the formation of ¹O₂ under aqueous conditions. Through use of the probe singlet oxygen sensor green (SOSG)³⁷ and methylene blue as a reference photosensitizer ($\Phi = 0.52$),^{38,39} the ability of **Pd[DMBil1]-PEG₇₅₀** to sensitize singlet oxygen was determined to be $\Phi \approx 0.23$ upon irradiation with 550 nm light (Table 1). The apparent attenuation of Φ in PBS relative to that in methanol is not surprising, given that detecting ¹O₂ in aqueous environments is more challenging due to its shorter lifetime^{40,41} as well as the lower solubility of oxygen in water as compared to organic solvents.⁴² Importantly, however, the aqueous Φ measured for **Pd[DMBil1]-PEG₇₅₀** is high enough to enable PDT in biological samples (vide infra).

TNBC accounts for ~15–20% of diagnosed breast cancer cases and is associated with earlier relapse, higher mortality rates, and significantly decreased progression-free survival compared to non-TN breast cancers.⁴³ TNBC patients are unsusceptible to available targeted or hormonal therapies, because the cells in these tumors do not express the necessary surface receptors. Therefore, these patients are treated with aggressive chemotherapies and surgeries that have harmful side effects and are often unsuccessful, necessitating the development of new treatment strategies for this disease. Because of its high potency and specificity, PDT has been recognized as a promising therapeutic approach for TNBC.⁴⁴

To evaluate the inherent toxicity of **Pd[DMBil1]-PEG₇₅₀**, TNBC MDA-MB-231 cells were treated with up to 5.0 mM **Pd[DMBil1]-PEG₇₅₀** for 48 h in the dark and then subjected to an Alamar blue cell viability assay. MDA-MB-231 cells were completely viable at **Pd[DMBil1]-PEG₇₅₀** concentrations up to 0.5 mM (Figure 4A). Further, the lethal (LD) dose required for 50% cell death was found to be LD₅₀ = 1.87 mM, an exceptionally high value, which demonstrates that, in the dark, **Pd[DMBil1]-PEG₇₅₀** is biocompatible and well-tolerated by the TNBC cells.

To further demonstrate the safety profile of **Pd[DMBil1]-PEG₇₅₀** and facilitate a comparison with a set of commercially available ¹O₂ photosensitizers that form the basis for common PDT treatments, cell viability assays were also conducted for hematoporphyrin dihydrochloride (HPDC) and isohematoporphyrin (IHP). Cell viability following treatment with up to 3.0 mM of either HPDC or IHP revealed lethal dose values of LD₅₀ = 1.22 mM and LD₅₀ = 0.64 mM, respectively, which are both lower than the LD₅₀ obtained for **Pd[DMBil1]-PEG₇₅₀** (Figure S5). These results demonstrate that **Pd[DMBil1]-PEG₇₅₀** is less toxic than two commercially available photosensitizers, suggesting that it may be used

as a photochemotherapeutic without causing off-target side effects that often limit the efficacy of PDT agents.

In an effort to assess whether **Pd[DMBil1]-PEG₇₅₀** is taken up by TNBC cells, MDA-MB-231 cells were treated with up to 1.5 mM **Pd[DMBil1]-PEG₇₅₀** for 48 h, and the cellular fluorescence was analyzed by fluorescence imaging and flow cytometry. As discussed above, **Pd[DMBil1]-PEG₇₅₀** retains the emission properties of **Pd[DMBil1]**, enabling its detection by fluorescence microscopy and flow cytometry. Fluorescence imaging revealed that **Pd[DMBil1]-PEG₇₅₀** is taken up by cells during the incubation period, as indicated by the red fluorescent signal (Figure 3). Further, flow cytometry analysis confirmed this result, as cells treated with **Pd[DMBil1]-PEG₇₅₀** experienced a twofold increase in median fluorescence intensity (MFI) compared to untreated cells (Figure S6). These results were encouraging given that cellular uptake is important for any compound to be used for PDT,⁴⁵ and they lead us to probe the efficacy of **Pd[DMBil1]-PEG₇₅₀** as a photochemotherapeutic agent.

To investigate the ability of **Pd[DMBil1]-PEG₇₅₀** to mediate PDT, MDA-MB-231 TNBC cells were treated with the biladiene complex at concentrations ranging from 0 to 10.0 μM for 4 h. At each concentration surveyed, cells were irradiated ($\lambda_{\text{ex}} > 500 \text{ nm}$) for either 0, 10, 20, or 30 min. Viability assays were conducted to assess cell death 16 h after irradiation. Cells incubated with **Pd[DMBil1]-PEG₇₅₀** for 24 h prior to irradiation were highly susceptible to PDT-mediated cell death compared to cells irradiated immediately after adding **Pd[DMBil1]-PEG₇₅₀**. More specifically, cells irradiated immediately following the addition of **Pd[DMBil1]-PEG₇₅₀** required concentrations of at least 1 μM and 30 min of light exposure before any loss of cell viability was observed (Figure S7). By contrast, cells incubated with **Pd[DMBil1]-PEG₇₅₀** for 24 h prior to light application were susceptible to PDT with concentrations of photosensitizer as low as 0.25 μM , and 10 μM treatment resulted in complete loss of viability (Figure 4B). This enhancement in photoinduced toxicity in cells incubated with the photosensitizer before light treatment provides further evidence of cellular uptake of **Pd[DMBil1]-PEG₇₅₀**. From these results, we also determined that the effective dose (ED) of **Pd[DMBil1]-PEG₇₅₀** required to reduce cell viability by 50% to be $\text{ED}_{50} = 0.354 \mu\text{M}$ for cells incubated with the photosensitizer for 24 h and then subjected to 30 min of light exposure. The ratio of $\text{LD}_{50}/\text{ED}_{50}$ delivers the phototoxicity index (PI) of a given photochemotherapeutic agent, which provides an indication of the potency of a photodrug in relation to its inherent dark toxicity. For **Pd[DMBil1]-PEG₇₅₀** the phototoxicity index is determined to be $\text{PI} \approx 5300$, which is exceptionally high,⁴⁶ especially when compared to porphyrinoids typically employed for PDT (vide infra).

To compare the phototoxicity index of **Pd[DMBil1]-PEG₇₅₀** with those for the commercially available photosensitizers, we conducted the same photodynamic activity experiments with HPDC and IHP. Treatment of MDA-MB-231 cells with each photosensitizer for 24 h followed by a 30 min period of irradiation ($\lambda_{\text{ex}} > 500 \text{ nm}$) revealed effective doses of $\text{ED}_{50} = 48.65 \mu\text{M}$ for HPDC and $\text{ED}_{50} = 327.56 \mu\text{M}$ for IHP (Figure S8). The LD_{50} and ED_{50} values for HPDC and IHP correlate to phototoxicity indices of $\text{PI} \approx 25$ for HPDC and $\text{PI} \approx 2$ for IHP. By comparison, the phototoxicity index of **Pd[DMBil1]-**

PEG₇₅₀ is quite impressive, as it is ~200 and 3000 times higher than those of HPDC and IHP, respectively.

With the realization that **Pd[DMBil1]-PEG₇₅₀** is highly potent and effective for PDT via ¹O₂ sensitization, we sought to evaluate the mechanism by which the biladiene phototriggered cell death. Ideally PDT will induce cellular apoptosis as opposed to necrosis, as the latter can cause the release of intracellular compartments and local inflammation that can stimulate tumor growth.⁴⁷ By contrast, apoptosis is anti-inflammatory and therefore discourages disease progression.⁴⁸ To assess the mechanism by which **Pd[DMBil1]-PEG₇₅₀** photoinduces cell death, MDA-MB-231 cells were treated with 4.0, 6.0, or 8.0 μ M **Pd[DMBil1]-PEG₇₅₀** for 24 h, irradiated for 30 min ($\lambda_{\text{ex}} > 500$ nm), and then incubated for 1 h prior to AnnexinV (fluorescein isothiocyanate (FITC) channel) and PI (PerCP channel) staining. Experiments in which none of the biladiene photosensitizer was added to the cells were also performed as controls. For these experiments, the MDA-MB-231 cells were treated with higher **Pd[DMBil1]-PEG₇₅₀** concentrations than in the viability experiments because we analyzed the cells only 1 h post light treatment (as opposed to overnight). Although these photosensitizer concentrations are higher than required for effective PDT, they are still more than 2 orders of magnitude lower than the LD₅₀ determined for **Pd[DMBil1]-PEG₇₅₀**. In these experiments, each mechanism of cell death appears in a distinct quadrant of Figure 5A depending on their level of staining. For example, live cells are negative for both FITC and PI (lower left quadrant), apoptotic cells stain positive for only FITC (lower right quadrant), late apoptotic cells stain positive for both FITC and PI (upper right quadrant), and necrotic cells stain positive for only PI (upper left quadrant).

The results of the apoptosis and necrosis assay show that PDT with **Pd[DMBil1]-PEG₇₅₀** induces primarily apoptotic cell death and that the percentage of apoptotic cells increases with higher photosensitizer concentrations (Figures 5 and S9). The maximum amount of positively stained cells resulted from treatment with 8.0 μ M **Pd[DMBil1]-PEG₇₅₀**. The average of three separate assays showed that 20.21% of cells were positive for early apoptosis, 17.08% of cells were positive for late apoptosis, and 8.17% of cells stained positive for necrosis only. Alternatively, cells that did not undergo light treatment experienced only minimal cell death by any mechanism. These results demonstrate that almost half of the total cell populations treated with **Pd[DMBil1]-PEG₇₅₀** that are exposed to light for 30 min experience primarily apoptotic cell death, and ~82% of the cells killed by the phototreatment expire via apoptosis rather than necrosis. Given that apoptosis is much preferred over necrosis for cancer treatment, these results make **Pd[DMBil1]-PEG₇₅₀** even more attractive as a potential photosensitizer for use in PDT.

CONCLUSIONS AND FUTURE DIRECTIONS

The development of new biologically compatible ¹O₂ sensitizers for use as PDT agents remains a topic of significant interest,⁴⁹ given the benefits that phototherapeutics can hold over more conventional treatment options for certain cancers. Despite these advantages and the fact that PDT has been approved to treat cancers of the skin, head, neck, digestive system, ovaries, prostate, bladder, lungs, breast, and brain,² its adoption as a mainstream cancer treatment has been hampered by a general lack of ¹O₂ photosensitizers that are

efficient, biologically tolerated, and pose minimal side effects and toxicity in the dark. In this work we described our efforts to address these shortcomings through development of a water-soluble dimethylbiladiene derivative (**Pd[DMBil1]-PEG₇₅₀**) that can sensitize the formation of singlet O₂ with high quantum yield under biologically relevant conditions.

Preparation of the **Pd[DMBil1]-PEG₇₅₀** complex was accomplished in two straightforward, high-yielding steps from the parent palladium dimethylbiladiene complex, and photo-physical studies revealed that PEGylation of the tetrapyrrole core has little effect on the electronic properties of the parent **Pd[DMBil1]** complex. In the absence of oxygen, **Pd[DMBil1]-PEG₇₅₀** displays both fluorescence and phosphorescence when dissolved in methanol. Notably, the triplet emission signal is completely quenched upon introduction of air to the sample due to efficient sensitization of ¹O₂ with a quantum yield of $\Phi = 0.57$, which is competitive with traditional sensitizers employed for PDT, including Photofrin.

Pd[DMBil1]-PEG₇₅₀ is highly soluble in water as well as in biological media. Measurement of the photophysical properties of **Pd[DMBil1]-PEG₇₅₀** in pH 7.4 PBS solutions showed that the complex does not aggregate and can photosensitize ¹O₂ under aqueous conditions. The efficacy of **Pd[DMBil1]-PEG₇₅₀** as a photochemotherapeutic agent was assessed using TNBC MDA-MB-231 cells, which readily take up the biladiene construct as evidenced by fluorescence microscopy and flow cytometry. In the dark, the **Pd[DMBil1]-PEG₇₅₀** complex is extremely well-tolerated by the TNBC cells and has an LD₅₀ of 1.87 mM. By contrast, the PEGylated palladium biladiene is an exceptionally potent photochemotherapeutic agent, as the effective dose of this complex required to reduce the TNBC viability by 50% was determined to be ED₅₀ = 0.354 μ M after 30 min of irradiation. Consideration of both the ED₅₀ and LD₅₀ metrics delivers the PI of **Pd[DMBil1]-PEG₇₅₀**, which is a benchmark of the efficacy of a photochemotherapeutic agent in relation to its inherent dark toxicity. **Pd[DMBil1]-PEG₇₅₀** has a remarkably high phototoxicity index of PI $\approx$ 5300. This value dwarfs those determined for molecular surrogates of existing commercial PDT agents, as HPDC and IHP were found to have phototoxicity indices of just PI $\approx$ 25 and PI $\approx$ 2, respectively.

Since comparison of the PI of **Pd[DMBil1]-PEG₇₅₀** to those for common porphyrin-based PDT models suggests that the linear palladium(II) tetrapyrrole can be a vastly superior photochemotherapeutic agent, the mechanism by which **Pd[DMBil1]-PEG₇₅₀** phototriggered TNBC cell death was probed. Cell death assays show that PDT with **Pd[DMBil1]-PEG₇₅₀** induces primarily apoptotic cell death as opposed to necrosis, as $\sim$ 82% of the TNBC cells that die as a result of PDT do so via apoptosis. This finding serves to further distinguish **Pd[DMBil1]-PEG₇₅₀** as a photochemotherapeutic agent, since apoptosis is much preferred over necrosis for cancer treatments, because the latter can result in local inflammation that stimulates tumor growth.

When viewed as a whole, this study demonstrates that **Pd[DMBil1]-PEG₇₅₀** holds promise as a photochemotherapeutic agent and should warrant further investigation as a PDT photosensitizer for treatment of cancers including TNBC. From a broader perspective, while macrocyclic tetrapyrroles such as porphyrins and phthalocyanines have been well-studied as potential PDT agents, this work demonstrates that properly engineered linear oligopyrrole

complexes may represent a privileged class of $^1\text{O}_2$ sensitizers for the treatment of human disease. Building off our findings that **Pd[DMBil1]-PEG₇₅₀** is well-tolerated by TNBC cells and is a potent $^1\text{O}_2$ sensitizer, future efforts will be focused on pushing the absorption envelope for this and related complexes further into the therapeutic window, either via modulation of the tetrapyrrole core or by using photon upconversion strategies, to better enable the use of such platforms in tissue and animal models.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGMENTS

A Strategic Initiatives Grant from the Univ. of Delaware (UD) Research Foundation and the State of Delaware Federal Research and Development Grant Program (16A00471) supported portions of this work. This work was also supported through NSF CAREER Award Nos. CHE1352120 and NIH P20GM104316. NMR and other data were acquired at UD using instrumentation obtained with assistance from the NSF and NIH (NSF-MIR 0421224, NSF-MIR 1048367, NSF-CRIF MU CHE-0840401 and CHE-0541775, NIH P20 RR017716). R.S.R. received support from the Univ. of Delaware Graduate Fellowship and from the American Association of Univ. Women.

REFERENCES

- (1). Knoll JD; Albani BA; Turro C New Ru(II) Complexes for Dual Photoreactivity: Ligand Exchange and $^1\text{O}_2$ Generation. *Acc. Chem. Res* 2015, 48, 2280–2287. [PubMed: 26186416]
- (2). Agostinis P; Berg K; Cengel KA; Foster TH; Girotti AW; Gollnick SO; Hahn SM; Hamblin MR; Juzeniene A; Kessel D; Korbelik M; Moan J; Mroz P; Nowis D; Piette J; Wilson BC; Golab J Photodynamic Therapy of Cancer: An Update. *Ca-Cancer J. Clin* 2011, 61, 250–281. [PubMed: 21617154]
- (3). Ozog DM; Rkein AM; Fabi SG; Gold MH; Goldman MP; Lowe NJ; Martin GM; Munavalli GS Photodynamic Therapy: A Clinical Consensus Guide. *Dermatol. Surg* 2016, 42, 804–827. [PubMed: 27336945]
- (4). Wang H; Xu Y; Shi J; Gao X; Geng L Photodermatol., Photoimmunol. Photomed 2015, 31, 44–53. [PubMed: 25377432]
- (5). Miltenburg NC; Boogerd W Chemotherapy-Induced Neuropathy: A Comprehensive Survey. *Cancer Treat. Rev* 2014, 40, 872–882. [PubMed: 24830939]
- (6). Love RR; Leventhal H; Easterling DV; Nerenz DR Side Effects and Emotional Distress During Cancer Chemotherapy. *Cancer* 1989, 63, 604–612. [PubMed: 2912536]
- (7). Lau TKH; Yip CHW; Yeo W State of the Art Antiemetic Therapy for Cancer Patients. *Curr. Oncol. Rep* 2016, 18, 1–13. [PubMed: 26694922]
- (8). Armstrong GT; Stovall M; Robison LL Long-Term Effects of Radiation Exposure among Adult Survivors of Childhood Cancer: Results from the Childhood Cancer Survivor Study. *Radiat. Res* 2010, 174, 840–850. [PubMed: 21128808]
- (9). Khan HA; Alhomida AS A Review of the Logistic Role of ν -carnitine in the Management of Radiation Toxicity and Radiotherapy Side Effects. *J. Appl. Toxicol* 2011, 31, 707–713. [PubMed: 21818761]
- (10). Nowis D; Stoklosa T; Legat M; Issat T; Jakobisiak M; Golab J The Influence of Photodynamic Therapy on the Immune Response. *Photodiagn. Photodyn. Ther* 2005, 2, 283–298.
- (11). Castano AP; Mroz P; Hamblin MR Photodynamic Therapy and Anti-Tumor Immunity. *Nat. Rev. Cancer* 2006, 6, 535–545. [PubMed: 16794636]
- (12). Bonnett R Photosensitizers of the Porphyrin and Phthalocyanine Series for Photodynamic Therapy. *Chem. Soc. Rev* 1995, 24, 19–33.
- (13). Ormond AB; Freeman HS Dye Sensitizers for Photodynamic Therapy. *Materials* 2013, 6, 817–840. [PubMed: 28809342]

- (14). O'Connor AE; Gallagher WM; Byrne AT Porphyrin and Nonporphyrin Photosensitizers in Oncology: Preclinical and Clinical Advances in Photodynamic Therapy. *Photochem. Photobiol* 2009, 85, 1053–1074. [PubMed: 19682322]
- (15). Potocny AM; Pistner AJ; Yap GPA; Rosenthal J Electrochemical, Spectroscopic, and $^1\text{O}_2$ Sensitization Characteristics of Synthetically Accessible Linear Tetrapyrrole Complexes of Palladium and Platinum. *Inorg. Chem* 2017, 56, 12703–12711. [PubMed: 28991441]
- (16). Li W; Zhan P; De Clercq E; Lou H; Liu X Current Drug Research on PEGylation with Small Molecular Agents. *Prog. Polym. Sci* 2013, 38, 421–444.
- (17). Greenwald RB; Choe YH; McGuire J; Conover CD Effective Drug Delivery by PEGylated Drug Conjugates. *Adv. Drug Delivery Rev* 2003, 55, 217–250.
- (18). Working PK; Newman MS; Johnson J; Cornacoff JB In Poly(ethylene glycol) Chemistry and Biological Applications; Harris JM, Zalipsky S, Eds.; American Chemical Society: Washington, DC, 1997; pp 45–57.
- (19). Powell GM In Handbook of Water Soluble Gums and Resins; Davidson RL, Crawford HB, Williams J, Eds.; McGraw-Hill: New York, 1980; pp 18–8–18–14.
- (20). Pistner AJ; Pupillo RC; Yap GPA; Lutterman DA; Ma YZ; Rosenthal J Electrochemical, Spectroscopic and Singlet Oxygen Sensitization Characteristics of 10,10-Dimethylbiladiene Complexes of Zinc and Copper. *J. Phys. Chem. A* 2014, 118, 10639–10648. [PubMed: 25187099]
- (21). Pistner AJ; Yap GP; Rosenthal J A Tetrapyrrole Macrocycle Displaying a Multielectron Redox Chemistry and Tunable Absorbance Profile. *J. Phys. Chem. C* 2012, 116, 16918–1692.
- (22). Pistner AJ; Lutterman DA; Ghidui MJ; Ma YZ; Rosenthal J Synthesis, Electrochemistry and Photophysics of a Family of Phlorin Macrocycles that Display Cooperative Fluoride Binding. *J. Am. Chem. Soc* 2013, 135, 6601–6607. [PubMed: 23594346]
- (23). Pistner AJ; Lutterman DA; Ghidui MJ; Walker E; Yap GPA; Rosenthal J Factors Controlling the Spectroscopic Properties and Supramolecular Chemistry of an Electron Deficient 5,5-Dimethylphlorin Architecture. *J. Phys. Chem. C* 2014, 118, 14124–14132.
- (24). Bhupathiraju NVSDK; Rizvi W; Batteas JD; Drain CM Fluorinated Porphyrinoids as Efficient Platforms for New Photonic Materials, Sensors, and Therapeutics. *Org. Biomol. Chem* 2016, 14, 389–408. [PubMed: 26514229]
- (25). Costa JIT; Tomé AC; Neves MGPM; Cavaleiro JAS 5,10,15,20-tetrakis(pentafluorophenyl)porphyrin: a Versatile Platform to Novel Porphyrinic Materials. *J. Porphyrins Phthalocyanines* 2011, 15, 1116–1133.
- (26). Rosenthal J; Schuster DI The Anomalous Reactivity of Fluorobenzene in Electrophilic Aromatic Substitution and Related Phenomena. *J. Chem. Educ* 2003, 80, 679–690.
- (27). Han S-Y; Kim Y-A Recent Development of Peptide Coupling Reagents in Organic Synthesis. *Tetrahedron* 2004, 60, 2447–2467.
- (28). Albeiiicio F; Chinchilla R; Dodsworth DJ; Nájera C New Trends in Peptide Coupling Reagents. *Org. Prep. Proced. Int* 2001, 33, 203–313.
- (29). Leighton P; Cowan JA; Abraham RJ; Sanders JKM Geometry of Porphyrin-Porphyrin Interactions. *J. Org. Chem* 1988, 53, 733–740.
- (30). Reddi E; Jori G Steady-State and Time-Resolved Spectroscopic Studies of Photodynamic Sensitizers: Porphyrins and Phthalocyanines. *Rev. Chem. Intermed* 1988, 10, 241–268.
- (31). Matsubara S; Kunieda M; Wada A; Sasaki S; Tamiaki H Visible and Near-Infrared Spectra of Chlorosomal Zinc Chlorin Self-Aggregates Dependent on Their Peripheral Substituents at the 8-position. *J. Photochem. Photobiol., A* 2016, 330, 195–199.
- (32). White WI In The Porphyrins; Dolphin D, Ed.; Academic Press: New York, 1978; Vol. 5: Physical Chemistry, Part C, pp 303–339.
- (33). Siggel U; Bindig U; Endisch C; Komatsu T; Tsuchida E; Voigt J; Fuhrhop J-H Photophysical and Photochemical Properties of Porphyrin Aggregates. *Ber. Bunsenges. Phys. Chem* 1996, 100, 2070–2075.
- (34). Young RH; Wehrly D; Martin RL Solvent Effects in Dye-Sensitized Photooxidation Reactions. *J. Am. Chem. Soc* 1971, 93, 5774–5779.

- (35). Bhattacharyya K; Das PK Quantitative Aspects of All-Trans-Retinol Singlet and Triplet Quenching by Oxygen. Chem. Phys. Lett 1985, 116, 326–332.
- (36). Li SP-Y; Lau CT-S; Louie M-W; Lam Y-W; Cheng SH; Lo KK-W Mitochondria-Targeting Cyclometalated Iridium-(III) – PEG Complexes with Tunable Photodynamic Activity. Biomaterials 2013, 34, 7519–7532. [PubMed: 23849346]
- (37). Ragàs X; Jiménez-Banzo A; Sánchez-García D; Batllori X; Nonell S Singlet Oxygen Photosensitization by the Fluorescent Probe Singlet Oxygen Sensor Green. Chem. Commun 2009, 20, 2920–2922.
- (38). Nemoto M; Kokubun H; Koizumi M Determination of the S*-T Transition Probabilities of Some Xanthene and Thiazine Dyes on the Basis of T-Energy Transfer. II. Results in the Aqueous Solution. Bull. Chem. Soc. Jpn 1969, 42, 2464–2470.
- (39). Usui Y; Kamogawa K A Standard System to Determine the Quantum Yield of Singlet Oxygen Formation in Aqueous Solution. Photochem. Photobiol 1974, 19, 245–247.
- (40). Egorov SY; Kamalov VF; Koroteev NI; Krasnovsky AA, Jr.; Toleutaev BN; Zinukov SV Rise and Decay Kinetics of Photosensitized Singlet Oxygen Luminescence in Water. Measurements with Nanosecond Time-Related Single Photon Counting Technique. Chem. Phys. Lett 1989, 163, 421–424.
- (41). Cheng C-C; Wu G-R; Chiou C-S; Yu J-K; Chou P-T Time-Resolved Thermal Lensing Studies on Metastable Species. J. Chin. Chem. Soc 2003, 50, 31–39.
- (42). Quaranta M; Murkovic M; Klimant I A New Method to Measure Oxygen Solubility in Organic Solvents Through Optical Oxygen Sensing. Analyst 2013, 138, 6243–6245. [PubMed: 23803965]
- (43). Griffiths C; Olin J Triple Negative Breast Cancer: A Brief Review of its Characteristics and Treatment Options. J. Pharm. Pract 2012, 25, 319–323. [PubMed: 22551559]
- (44). Shemesh C; Hardy C; Yu D; Fernandez B; Zhang H Indocyanine Green Loaded Liposome Nanocarriers for Photodynamic Therapy Using Human Triple Negative Breast Cancer Cells. Photodiagn. Photodyn. Ther 2014, 11, 193–203.
- (45). Castano A; Demidova T; Hamblin M Mechanisms in Photodynamic Therapy: Part One- Photosensitizers, Photochemistry and Cellular Localization. Photodiagn. Photodyn. Ther 2004, 1, 279–293.
- (46). Mroz P; Yaroslavsky A; Kharkwal GB; Hamblin H Cell Death Pathways in Photodynamic Therapy of Cancer. Cancers 2011, 3, 2516–2539. [PubMed: 23914299]
- (47). Melamed J; Edelstein R; Day E Elucidating the Fundamental Mechanisms of Cell Death Triggered by Photothermal Therapy. ACS Nano 2015, 9, 6–11. [PubMed: 25590560]
- (48). Albani BA; Peña B; Leed NA; de Paula NABG; Pavani C; Baptista MS; Dunbar KR; Turro C Marked Improvement in Photoinduced Cell Death by a New Tris-heteroleptic Complex with Dual Action: Singlet Oxygen Sensitization and Ligand Dissociation. J. Am. Chem. Soc 2014, 136, 17095–17101. [PubMed: 25393595]
- (49). Loftus LM; White JK; Albani BA; Kohler L; Kodanko JJ; Thummel RP; Dunbar KR; Turro C New Ru^{II} for Dual Activity: Photoinduced Ligand Release and ¹O₂ Production. Chem. - Eur. J 2016, 22, 3704–3708. [PubMed: 26715085]

Figure 1. Electronic absorption spectra of **Pd[DMBil1]** in methanol (black line), **Pd[DMBil1]-PEG₇₅₀** in methanol (red line), and **Pd[DMBil1]-PEG₇₅₀** in pH 7.4 PBS (dashed blue line).

Figure 2.
Emission spectra following excitation with 500 nm light of (a) **Pd[DMBil1]** and (b) **Pd[DMBil1]-PEG₇₅₀** in methanol at 298 K under an atmosphere of air (black) or nitrogen (red).

Figure 3.

Fluorescence images showing **Pd[DMBi1]-PEG₇₅₀** uptake by MDA-MB-231 cells following a 24 h incubation period. Nuclei are stained blue (DAPI), F-actin in the cytoskeleton is stained green (phalloidan), and **Pd[DMBi1]-PEG₇₅₀** appears red. Scale = 25 μm .

Figure 4.

Normalized cell viability after incubation with **Pd-[DMBil1]-PEG₇₅₀** for (a) 48 and (b) 24 h followed by light exposure for 0 (black), 10 (red), 20 (beige), or 30 (blue) min. Cells were incubated overnight post-irradiation and prior to the viability analyses. **p* < 0.0001 by two-way ANOVA with post hoc Tukey-Kramer compared to 0 min light exposure for each concentration.

Figure 5. Apoptosis and necrosis assay after incubation with 0.0, 4.0, 6.0, or 8.0 μM of **Pd[DMBi1]-PEG₇₅₀** for 24 h, followed by light treatment for 30 min and incubation for 1 h. (A) Representative flow cytometry density plot of cells treated with 8.0 μM **Pd[DMBi1]-PEG₇₅₀**. (B–D) Flow cytometry analysis of cell populations in early apoptosis, late apoptosis, and necrosis following treatment with the photosensitizer. * $p < 0.05$ by t -tests compared to no light treatment for each concentration.

Scheme 1. Photodynamic Therapy^a

^aPhotosensitizers are intravenously or intratumorally administered. The tumor area is then irradiated, driving the formation of toxic 1O_2 to irreversibly damage/kill the surrounding cells.

Scheme 2.

Synthesis of Pd[DMBi1], Pd[DMBi1]-SCH₂CO₂H, and Pd[DMBi1]-PEG₇₅₀

Table 1.

Photophysical Properties of Pd[DMBiI] Complexes

compound (solvent)	λ_{abs} , nm ($\epsilon \times 10^3 \text{ M}^{-1} \text{ cm}^{-1}$)	λ_{fl} , nm (Φ_{fl})	λ_{ph} , nm (Φ_{ph})	Φ ^a
Pd[DMBiI] (methanol)	401 (17.4), 483 (31.9), 540 (7.5)	557 (1.3×10^{-4})	753 (1.3×10^{-4})	0.80
Pd[DMBiI]-PEG₇₅₀ (methanol)	402 (16.6), 483 (34.6), 540 (7.5)	568 (1.4×10^{-4})	756 (7.8×10^{-5})	0.57
Pd[DMBiI]-PEG₇₅₀ (PBS)	405 (13.6), 496 (33.2), 551 (8.3)	580 (2.0×10^{-4})		0.23

^a Measured upon irradiation with $\lambda_{\text{exc}} = 500$ nm.